Global Markets Direct's, 'Leukemias - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Leukemias, complete with latest updates, and special features on late-stage and discontinued projects. https://www.reportscorner.com/reports/23242/Leukemias-%E2%80%93-Pipeline-Review,-H1-2013/

1. RC
Reports Corner
Leukemias – Pipeline Review, H1 2013

2. DescriptionDescription
Reports Cornerwww.reportscorner.com
Global Markets Direct's, 'Leukemias - Pipeline Review, H1 2013',
provides an overview of the indication's therapeutic pipeline. This
report provides information on the therapeutic development for
Leukemias, complete with latest updates, and special features on
late-stage and discontinued projects.

3. Brief SummaryBrief Summary
Reports Cornerwww.reportscorner.com
Global Markets Direct's, 'Leukemias - Pipeline Review, H1 2013',
provides an overview of the indication's therapeutic pipeline. This
report provides information on the therapeutic development for
Leukemias, complete with latest updates, and special features on
late-stage and discontinued projects. It also reviews key players
involved in the therapeutic development for Leukemias.
Leukemias - Pipeline Review, Half Year is built using data and
information sourced from Global Markets Direct's proprietary
databases, Company/University websites, SEC filings, investor
presentations and featured press releases from
company/university sites and industry-specific third party
sources, put together by Global Markets Direct's team.
Note*: Certain sections in the report may be removed or altered
based on the availability and relevance of data for the indicated
disease.

4. Brief SummaryBrief Summary
Reports Cornerwww.reportscorner.com
Scope
- A snapshot of the global therapeutic scenario for Leukemias.
- A review of the Leukemias products under development by
companies and universities/research institutes based on
information derived from company and industry-specific sources.
- Coverage of products based on various stages of development
ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and
combined therapeutics.
- Coverage of the Leukemias pipeline on the basis of route of
administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

5. Brief SummaryBrief Summary
Reports Cornerwww.reportscorner.com
Reasons to buy
- Identify and understand important and diverse types of
therapeutics under development for Leukemias.
- Identify emerging players with potentially strong product
portfolio and design effective counter-strategies to gain
competitive advantage.
- Plan mergers and acquisitions effectively by identifying players
of the most promising pipeline.
- Devise corrective measures for pipeline projects by
understanding Leukemias pipeline depth and focus of Indication
therapeutics.
- Develop and design in-licensing and out-licensing strategies by
identifying prospective partners with the most attractive projects
to enhance and expand business potential and scope.

6. Brief SummaryBrief Summary
Reports Cornerwww.reportscorner.com
- Modify the therapeutic portfolio by identifying discontinued
projects and understanding the factors that drove them from
pipeline.

7. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
Table of Contents
Table of Contents 2
List of Tables 8
List of Figures 10
Introduction 11
Global Markets Direct Report Coverage 11
Leukemias Overview 12
Therapeutics Development 13
An Overview of Pipeline Products for Leukemias 13
Leukemias Therapeutics under Development by Companies 15
Leukemias Therapeutics under Investigation by Universities/Institutes 23
Late Stage Products 26
Comparative Analysis 26
Mid Clinical Stage Products 27
Comparative Analysis 27

8. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
Early Clinical Stage Products 28
Comparative Analysis 28
Discovery and Pre-Clinical Stage Products 29
Comparative Analysis 29
Leukemias Therapeutics – Products under Development by Companies 30
Leukemias Therapeutics – Products under Investigation by Universities/Institutes 38
Companies Involved in Leukemias Therapeutics Development 40
Boehringer Ingelheim GmbH 40
Amgen Inc. 41
Eli Lilly and Company 42
Athersys, Inc. 43
GlaxoSmithKline plc 44
Seattle Genetics, Inc. 45
MedImmune LLC 46
Daiichi Sankyo Company, Ltd 47

9. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
Emergent BioSolutions Inc. 48
Gamida Cell Ltd. 49
BioLineRx, Ltd. 50
Amorfix Life Sciences Ltd. 51
Bio-Path Holdings, Inc. 52
ZIOPHARM Oncology, Inc. 53
Novartis AG 54
Aphios Corporation 55
CK Life Sciences Int'l., (Holdings) Inc. 56
Daewoong Pharmaceutical Co., Ltd. 57
Genta Incorporated 58
GTC Biotherapeutics, Inc. 59
Nippon Shinyaku Co., Ltd. 60
Ono Pharmaceutical Co., Ltd. 61
Pfizer Inc. 62

10. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
SuperGen, Inc. 63
Teva Pharmaceutical Industries Limited 64
Genmab A/S 65
Merck KGaA 66
Celldex Therapeutics, Inc. 67
Marshall Edwards, Inc. 68
MethylGene Inc 69
Northwest Biotherapeutics, Inc. 70
Telik, Inc. 71
Mundipharma International Limited 72
Pharmacyclics, Inc. 73
Cytomedix, Inc. 74
Array BioPharma Inc. 75
Threshold Pharmaceuticals, Inc. 76
CrystalGenomics, Inc.

11. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
Sareum Holdings plc 78
MetrioPharm AG 79
SymBio Pharmaceuticals Limited 80
Abiogen Pharma S.p.A. 81
Multimmune GmbH 82
Nerviano Medical Sciences S.r.l. 83
ViroStatics, srl 84
MAT Biopharma 85
Celator Pharmaceuticals, Inc. 86
Hawthorn Pharmaceuticals, Inc. 87
ACT Biotech, Inc. 88
Constellation Pharmaceuticals, Inc. 89
Deciphera Pharmaceuticals, LLC 90
MSM Protein Technologies, Inc. 91
Reata Pharmaceuticals, Inc. 92

12. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
Stemline Therapeutics, Inc. 93
Synageva BioPharma Corp. 94
MolMed S.p.A. 95
NOXXON Pharma AG 96
Morphogenesis, Inc. 97
SBI Biotech Co., Ltd. 98
Tragara Pharmaceuticals, Inc. 99
Cellceutix Corporation 100
PharmaMar, S.A. 101
Cylene Pharmaceuticals, Inc. 102
Lipopharma 103
Keystone Nano, Inc. 104
Toko Pharmaceutical Industries Co., Ltd. 105
Cancer Therapeutics CRC Pty Ltd 106
EpiZyme, Inc. 107

13. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
Shanghai Fudan-zhangjiang Bio-Pharmaceutical Co.,Ltd. 108
iCeutica, Inc. 109
Polaris Group 110
XBiotech USA, Inc. 111
Wellstat Biologics Corporation 112
Immunovative Therapies, Ltd. 113
Advancell 114
Leukemias – Therapeutics Assessment 115
Assessment by Monotherapy Products 115
Assessment by Combination Products 116
Assessment by Route of Administration 117
Assessment by Molecule Type 119
Drug Profiles 122
StemEx - Drug Profile 122
alvocidib - Drug Profile 124

14. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
oblimersen sodium - Drug Profile 125
moxetumomab pasudotox - Drug Profile 128
brentuximab vedotin - Drug Profile 130
CDX-1127 - Drug Profile 134
acadesine - Drug Profile 135
MultiStem - Drug Profile 137
mocetinostat - Drug Profile 140
ibrutinib - Drug Profile 143
ENKASTIM-ev - Drug Profile 146
mi-APO - Drug Profile 147
AT-9283 - Drug Profile 148
ALD-151 - Drug Profile 150
IMD-5 - Drug Profile 151
bafetinib - Drug Profile 152
cilengitide - Drug Profile 154

15. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
TRU-016 - Drug Profile 157
pracinostat - Drug Profile 159
TG-02 - Drug Profile 161
ARRY-520 - Drug Profile 163
forodesine hydrochloride - Drug Profile 165
CXCR4 Antibody - Drug Profile 167
TLK-58747 - Drug Profile 168
TG-20 - Drug Profile 169
TH-302 - Drug Profile 170
darinaparsin - Drug Profile 177
(cytarabine + daunorubicin) - Drug Profile 179
SL-202 - Drug Profile 181
SL-201 - Drug Profile 182
HSV-TK - Drug Profile 183
HSV-TK - Drug Profile 185

16. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
SBC-201 - Drug Profile 187
SyB-0702 - Drug Profile 188
NOX-A12 - Drug Profile 189
MG-1 - Drug Profile 191
Kevetrin - Drug Profile 192
BP-100-1.02 - Drug Profile 195
sirolimus + [decitabine] - Drug Profile 196
ACTB-1011 - Drug Profile 197
DI-B4 - Drug Profile 198
tamibarotene - Drug Profile 199
tamibarotene - Drug Profile 201
lurbinectedin - Drug Profile 203
bardoxolone - Drug Profile 205
Combotox - Drug Profile 207
silmitasertib - Drug Profile 208

17. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
PU-27 - Drug Profile 210
exatecan mesylate - Drug Profile 211
AMG-900 - Drug Profile 213
ADI-PEG 20 - Drug Profile 215
Allogeneic Epstein-Barr Virus-Specific Cytotoxic T Lymphocytes - Drug Profile 218
buparlisib - Drug Profile 220
palbociclib - Drug Profile 223
HGC-1 - Drug Profile 226
Autologous CD19 Specific T-cell Infusion + [cyclophosphamide] + [fludarabine phosphate] +
Leukapheresis - Drug Profile 227
PHA-793887 - Drug Profile 228
GNKG-168 - Drug Profile 229
Minerval - Drug Profile 231
ofatumumab - Drug Profile 233
XIAP-cIAP - Drug Profile 237
Anti-Tac(Fv)-PE38 Immunotoxin - Drug Profile 238

18. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
DNA Methyltransferase Inhibitor - Drug Profile 240
F-14512 - Drug Profile 241
CA-18-C-3 - Drug Profile 242
MAT-303 - Drug Profile 243
LY-2090314 - Drug Profile 244
Vivia-009 - Drug Profile 245
DCC-2618 - Drug Profile 246
GO-203-2c - Drug Profile 247
BI-836826 - Drug Profile 248
PRI-724 - Drug Profile 249
CEP-37309 - Drug Profile 250
ABT-199 - Drug Profile 251
Leukothera - Drug Profile 254
Interleukin-1 Receptor Associated Protein Targeting Antibody - Drug Profile 255
MSM-112 - Drug Profile 257

19. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
PQR-311 - Drug Profile 258
TBI-0301 - Drug Profile 259
Lenaldekar - Drug Profile 260
IC-1208 - Drug Profile 261
IB-05202 - Drug Profile 262
Drug Targeting FAK, FLT3 And VEGFR3 - Drug Profile 263
OTX-015 - Drug Profile 265
BL-8040 - Drug Profile 266
ONO-4059 - Drug Profile 268
NCL49-1 - Drug Profile 269
metformin - Drug Profile 270
Anti-CD19-CAR-Transduced T Cells - Drug Profile 271
ATX-101 - Drug Profile 272
Fas Program - Drug Profile 273
Monoclonal Antibodies Targeting CD38 - Drug Profile 274

20. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
vincristine sulfate liposomal - Drug Profile 275
JRP-890 - Drug Profile 276
JRP-980 - Drug Profile 277
VS-1020 - Drug Profile 278
VS-1022 - Drug Profile 279
VS-1023 - Drug Profile 280
VS-1032 - Drug Profile 281
VS-1033 - Drug Profile 282
VS-1034 - Drug Profile 283
VS-1035 - Drug Profile 284
V-SlOlO - Drug Profile 285
Drug Targeting Menin - Drug Profile 286
BET Inhibitor Program - Drug Profile 287
Tumor-Derived Lymphocytes + Allogeneic Hematopoietic Stem Cell Transplantation - Drug Profile 288
EPZ-004777 - Drug Profile 289

21. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
Microtubule Binding Agents Programme - Drug Profile 290
Aloe-Emodin Glycoside - Drug Profile 291
IB-06F259 - Drug Profile 292
Genetically Modified T Cell - Drug Profile 293
Compound-22 - Drug Profile 294
interferon alfa-2b biosimilar - Drug Profile 295
Reprogrammed T Cells - Drug Profile 296
VAY-736 - Drug Profile 297
CG-203306 - Drug Profile 298
SNG-8033 - Drug Profile 299
XGP-210 - Drug Profile 300
XGP-215 - Drug Profile 301
Drug For Leukemia - Drug Profile 302
Triplebody 19x16x19 - Drug Profile 303
Triplebody 123x16x33 - Drug Profile 304

22. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
Drugs For Cancer - Drug Profile 305
CKBP-002 - Drug Profile 306
MSK-777 - Drug Profile 307
MSK-747 - Drug Profile 308
PMA-411R - Drug Profile 309
PV-327 - Drug Profile 310
Halistatin-1 - Drug Profile 311
Mabion CD20 - Drug Profile 312
Halistatin-2 - Drug Profile 314
filgrastim - Drug Profile 315
TAB-08 - Drug Profile 316
etomoxir - Drug Profile 318
KU-135 - Drug Profile 319
Carbazole Derivatives - Drug Profile 320
Laulimalide Derivatives - Drug Profile 321

23. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
Cell Therapy For Leukemia - Drug Profile 322
Epothilone Analogues - Drug Profile 323
Compound-8f - Drug Profile 324
Compound-11d - Drug Profile 325
Leukemias Therapeutics – Drug Profile Updates 326
Leukemias Therapeutics – Discontinued Products 407
Leukemias Therapeutics - Dormant Products 408
Leukemias – Product Development Milestones 414
Featured News & Press Releases 414
Appendix 425
Methodology 425
Coverage 425
Secondary Research 425
Primary Research 425
Expert Panel Validation 425

24. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
Contact Us 426
Disclaimer 426

25. For more informationFor more information
Reports Cornerwww.reportscorner.com
For more information please visit our website
https://www.reportscorner.com/reports/23242/Leukemias-%E2%80%93-Pipeline-
Review,-H1-2013/

26. Reports Corner
Thank YouThank You
www.reportscorner.com
RC
Contact us: contact@reportscorner.com